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 Altered metabolism is a distinct feature of cancer cells. During transformation, the 
entire metabolic network is rewired to efficiently convert nutrients to biosynthetic 
precursors to sustain cancer cell growth and proliferation. Whilst the molecular 
underpinnings of this metabolic reprogramming have been described, its role in tumor 
progression is still under investigation. Importantly, the mitochondria is a central actor 
in many of the metabolic processes that are altered in tumors. Yet, we have only begun 
to understand the dualities of mitochondrial function during cancer metastasis and 
therapy resistance. Paradoxically, mitochondrial metabolism can be both 
advantageous and detrimental to these processes, highlighting the need for a better 
understanding of the molecular and micro-environmental cues that define the role of 
this fascinating organelle. In this review article, we present an updated view on the 
different mitochondrial metabolic strategies adopted by cancer cells to overcome the 
many hurdles faced during tumor progression. 
 
 Introduction 
Cancer is a multifaceted disease whose pathogenesis remains elusive, despite the series of 
breakthroughs since the discovery of the first oncogene, SRC, more than 50 years ago (see 
glossary) [1]. Although it was initially thought that a set of mutations in specific oncogenes 
and tumor suppressors was sufficient to drive tumorigenesis, the spontaneous accumulation 
of such mutations in otherwise healthy tissue [2] indicates that cell transformation is a process 
exceeding this initial simplistic view. Indeed, tumorigenesis is supported by acquisition of cell- 
and non-cell-autonomous traits, known as the hallmarks of cancer [3]. Among these, altered 
energy metabolism has recently gained some attention. Bolstered by the development of a 
variety of techniques to assess the cellular metabolome, it has been shown that during 
transformation cancer cells undergo profound metabolic changes, including activation of 
glycolysis, altered utilization of amino acids, and dysregulation of mitochondrial function [4]. 
The availability of large-scale datasets from The Cancer Genome Atlas (TCGA, 
https://cancergenome.nih.gov/) has allowed the identification of the underpinning genetic 
determinants of these metabolic changes, showing that they are orchestrated by well-known 
oncogenes and tumor suppressors [5]. Furthermore, it has been observed that tumors share 
a subset of metabolic gene signatures independent of their tissue of origin, and upregulate 
genes that encode for glycolysis and nucleotide biosynthesis enzymes [6, 7]. On the other 
hand, recent experiments using elegant mouse models showed that cancers also retain 
metabolic features from their tissue of origin [8].  
Mitochondria co-ordinate a large fraction of metabolic, energetic, and physiological 
processes, and their integrity is a central checkpoint for cancer cells [4]. In this respect, the 
finding that genetic alterations of mitochondrial metabolic enzymes, such as Fumarate 
Hydratase (FH), Succinate Dehydrogenase (SDH), and Isocitrate Dehydrogenase (IDH1/2) 
[9], can predispose or contribute to cancer shook the field. In fact, investigations on these 
models revealed that metabolites of mitochondrial origin accumulated in these tumors can 
activate oncogenic signaling cascades, making them bona fide oncometabolites [9]. In 
 addition to exacerbated or inhibited metabolite production, cancer cells also exploit the 
reversible nature of many metabolic reactions. In fact, beyond aberrant activation of glycolysis, 
the use of the tricarboxylic acid cycle in reversed mode (reductive carboxylation) enables the 
use of glutamine for biosynthetic purposes in cells with dysfunctional mitochondria [10, 11]. 
Interestingly, a compilation of experimental evidence suggest that mitochondrial dysfunction 
can reach a threshold where it turns from advantageous to detrimental for cancer cells. In this 
line, depletion of mitochondrial DNA (mtDNA) upon disruption of the mitochondrial 
transcription factor A (TFAM) inhibits mutant Kras-driven tumorigenesis in mice [12]. 
Furthermore, mtDNA-depleted cancer cells transplanted in mice acquire whole mitochondria 
from host cells via horizontal transfer as an strategy to restore their mitochondrial function 
[13]. These results indicate that changes in mitochondrial metabolism are not only mere 
consequences of transformation and that fine regulation of mitochondrial function is required 
to drive tumorigenesis. 
While the metabolic underpinnings of tumor initiation have been described for a wide range 
of tumor types, little is known on the metabolic adaptations that can occur at later phases of 
cancer progression. The aim of this review article is to focus on the initial evidence gathered 
in recent years about the role of mitochondrial metabolism during the stages following cancer 
initiation and accompanying cancer progression. Understanding how tumor cells rewire and 
adapt their mitochondrial metabolism during tumor progression could be instrumental both for 
the development of novel anticancer strategies and for the identification of aggressiveness 
signs of prognostic value  
 
Altered mitochondrial metabolism contributes to tumor progression 
The importance of metabolism in cancer is illustrated by the fact that tumors can be clustered 
based on their metabolic signature, with important implications for cancer diagnosis and 
patient stratification [7]. However, tumors are far from being a static entity. Environmental 
 constraints, such as nutrient and oxygen availability, and the exposure to anti-tumor agents, 
inevitably challenge the survival of cancer cells and force their evolution and/or selection within 
the tumor [14]. Indeed, recent evidence indicates that the metabolic phenotype of cancer 
varies at different disease stages, and it is a contributing factor for tumor progression (Figure 
1). For instance, an increase in glycolytic enzymes and a decrease in mitochondrial 
transcriptional programs has been observed at different stages of prostate cancer progression 
[15, 16]. Similarly, stage-specific metabolic traits were identified in breast [17], renal cancer 
[18], and lung cancer [19]. In this context, mitochondrial metabolism seems to play a key role. 
Transcriptional analysis of 21 tumor types collected by the TCGA revealed that the repression 
of genes related to mitochondrial metabolism is strikingly associated with poor clinical 
outcome and is associated with the presence of an epithelial to mesenchymal transition (EMT) 
gene signature, a molecular pathway linked to tumor initiation, invasion, and metastasis [24]. 
These results suggest that during tumor progression, mitochondrial dysfunction can be 
advantageous and could make cancer cells more motile and invasive, predisposing to 
metastasis. Complementary studies have showed that mutations of enzymes from the TCA 
cycle ,SDH and FH, are linked to the activation of EMT and invasive phenotype in 
pheochromocytoma and paraganglioma [25] and renal cancer [26]. Similarly, mtDNA 
abundance displays high heterogeneity among human tumors and mtDNA depletion, which is 
generally associated with bioenergetics defects, is linked with poor patient prognosis in 
several human cancers [27].  
Overall, these results indicate that the suppression of TCA cycle enzymes provides a 
distinct advantage to the cancer cells during tumor progression, and it can contribute to the 
clinical outcome of patients. However, there are also reported examples of mitochondrial 
dysfunction being detrimental for cancer aggressiveness. Studies performed on renal 
oncocytoma, a benign tumor characterized by aberrant accumulation of dysfunctional 
mitochondria, showed that defects in mitochondrial function can inhibit the autophagic 
machinery, thus creating a metabolic checkpoint that inhibits tumor progression [20]. 
 Conversely, activation of autophagy is fundamental to support mutant Ras-driven cancer cells 
by providing substrates for mitochondrial metabolism and clearing dysfunctional mitochondria 
[21-23]. Consistently, inhibition of autophagy leads to mitochondrial dysfunction and blocks 
malignant tumor progression by reprogramming tumor fate towards benign neoplasms [21]. 
With this new perspective of mitochondrial function as friend and foe for tumor 
progression, it will be important to define in future studies to which extent is this phenomenon 
the consequence of tissue or tumor-specific mitochondrial requirements. Alternatively, it could 
be the result of a byphasic contribution of this organelle to tumour progression, being the 
reduction in mitochondrial function progressively advantegous to cancer cells until it reaches 
a “minimal integrity point”, below which this alteration becomes detrimental.  
The dual role of mitochondrial metabolism in cancer cell dissemination and metastasis 
During tumor progression, epithelial cells face loss of anchorage to their native location, which 
triggers a stress response that leads to cell death in a process termed anoikis [28]. The bypass 
of this phenomenon requires a profound adaptation of cellular metabolism, which has been 
reviewed elsewhere [29]. In addition, once detached, cancer cells remain exposed to 
additional micro-environmental stresses in their journey to a foreign distant tissue to establish 
metastatic lesions. These challenges include the invasion beyond the basal membrane, 
intravasation (with the potential requirement of EMT), survival in circulation, extravasation, 
homing in a secondary organ and tumor regrowth [30] (Figure 2). This process is 
tremendously inefficient as the majority of maladapted cells die in circulation or upon reaching 
a hostile microenvironment. Yet, a small percentage of cells with intrinsic abilities or sufficient 
plasticity to adapt and survive upon intravasation can successfully colonize a secondary organ 
[30]. Once seeded, cancer cells re-enter a proliferative stage (a process that can take from 
weeks to years) and overcome the hostile environmental conditions to generate a 
disseminated tumor. Importantly, these cells will need to optimize their metabolic state 
 according to the characteristics of the target tissue, as well as to their own mutational 
background.  
The determinants of the metabolic adaptations during dissemination and metastasis are 
only partially known. In line with the increase in oxidative stress during anchorage-
independent growth [28, 31], it was recently shown that metastatic cells from primary 
melanoma require the activation of mitochondrial antioxidant pathways to survive [32]. In 
support of these findings, it was recently shown that cell detachment leads to a complex 
rewiring of nutrient utilization, with reductive carboxylation being a key pathway to generate 
antioxidant molecules [33, 34]. Overall, cancer cells that detach from the primary tumor 
experience oxidative stress and, by activating antioxidant pathways, they can overcome this 
challenge and eventually metastasize. This view is supported by the many examples with 
isolated antioxidant genes or chronic therapies with antioxidant properties that promote 
metastasis [35-41].  
The activation of specific transcriptional programs that regulate mitochondrial activity 
during cancer cell dissemination and metastasis underpins these metabolic changes. In 
prostate cancer, active mitochondrial oxidative metabolism represents a disadvantageous 
metabolic state for cancer cells and leads to tumor suppression [16]. Moreover, deletion of the 
master transcriptional regulator of mitochondrial oxidative metabolism, Peroxisome 
proliferator-activated receptor gamma coactivator 1 alpha (PGC1α), in the mouse prostate 
induces a glycolytic switch and promotes cancer progression and metastasis, in agreement 
with the down-regulation of PGC1α observed in human specimens [16]. Of note, striking 
similarities exist between prostate cancer specimens that will eventually recur and the 
metastatic lesions, in terms of the PGC1α-dependent metabolic program. These results 
suggest that the selection process for metabolically fit metastatic clones could start in primary 
tumors long before prostate cancer disseminates (Figure 2). Interestingly, in a complementary 
study in melanoma it was shown that PGC1α suppresses metastasis through the regulation 
of an adhesion and invasion transcriptional program [42]. In support of a role of mitochondrial 
 dysfunction in promoting metastasis, partial inhibition of mitochondrial respiratory chain with 
rotenone is sufficient to induce cell migration and clonogenicity in vitro and to support lung 
metastasis in vivo [43]. Finally, mtDNA mutations affecting complex I have been found to 
support breast cancer metastasis in vivo via de-regulation of NAD+/NADH and activation of 
autophagy. Importantly, rescue of mitochondrial function through enhancement of complex I 
activity could inhibit formation of metastasis[44]. 
Despite these consistent lines of evidence, the role of mitochondrial function in metastasis 
remains controversial. For instance, increased mitochondrial function was detected in 
circulating cells from orthotopically-implanted breast cancer [45], suggesting that tumor-
specific reprogramming might occur during metastasis. The same study showed that 
establishment of metastases was accompanied by decrease expression of OXPHOS genes, 
thus adding complexity to the role of mitochondrial function in the survival of matrix-detached 
cells and distant tissue colonization [45]. Of note, differential use of pyruvate in the 
mitochondria has been recently shown to dictate the site of metastasis in breast cancer [46, 
47]. Breast-cancer-derived lung metastases showed increase dependency on pyruvate 
conversion into oxaloacetate through Pyruvate Carboxylase activation [46]. Liver-metastatic 
cells, however, divert pyruvate into lactate production as a result of increased activity of 
Pyruvate Dehydrogenase Kinase 1 [47]. These results suggest that metastatic cells undergo 
adaptations that are dictated by the different metabolic landscapes of target tissues and call 
for a careful analysis of metastatic site-dependent metabolic rewiring.  
Changes in mitochondrial function are inherently linked with the increased requirement of 
antioxidant molecules of disseminated cells that we described above. Multiple strategies can 
be adopted to increase antioxidant power (Figure 2). On the one hand, a decrease in 
mitochondrial activity would result in reduced production of mitochondrial free radicals. This is 
the proposed mechanism in melanoma [32], where cells activate compensatory antioxidant 
mechanisms (folate metabolism, the main producer of reducing power [48]). On the other 
hand, activation of PGC1α pathway would result in increased mitochondrial metabolism and 
 activation of an antioxidant program, which would counteract oxidative stress. This strategy is 
observed in breast cancer [45], and is in line with other studies pointing at the enhanced 
antioxidant response activated upon induction of PGC1α [49]. Therefore, cancer cells with 
different genetic drivers or tissue-of-origin constrains might differ in the optimal metabolic state 
that counteracts oxidative stress and supports the sequential process of metastasis. Finally, 
a recent study highlighted the link between epigenetic changes occurring in PDAC metastases 
and reprogramming of the oxidative branch of the pentose phosphate pathway [50], thus 
indicating that epigenetic mechanisms might control the antioxidant capacity of metastatic 
cells. Overall, these studies increase the complexity of the oncogenic activity of metabolic 
programs and call for caution when defining a dogmatic and static oncogenic metabolic 
reprogramming.  
Metabolic adaptation contributes to therapy resistance 
As discussed above, the ability to adapt the metabolic phenotype at different stages of the 
disease is a clear advantage for cancer cells. This metabolic modulation is also key when 
cancer cells are subject to the toxic effects of anticancer drugs. Indeed, specific metabolic 
features of cancer cells can overcome the toxic effects of anticancer drugs, leading to 
chemoresistance [51-57] or support lipid synthesis and mutagenesis in these challenging 
conditions [58] (Figure 3). For instance, cisplatin resistance is driven by a metabolic 
reprogramming that supports the generation of antioxidant molecules, including NADPH via 
the pentose phosphate pathway [51] and glutathione biosynthesis from glutamine [53]. 
Resistance to oncogene addiction [55] has been also shown to rely on metabolic adaptation. 
In this model, the extinction of mutant KRas in established tumors leads to the selection of a 
subpopulation of resistant cells dependent on mitochondrial metabolism [55]. Similar findings 
have been made in melanoma, in which inhibition of BRafV600 in BRaf V600-driven melanoma 
induces an oxidative phosphorylation switch orchestrated by PGC1α [49, 52], enhancing the 
detoxification capacities of these cells. In addition, resistance to MAPK inhibitors in this type 
of cancer is associated with increase mitochondrial DNA content and oxidative 
 phosphorylation [57]. These results are in support of a role of activated mitochondrial function 
as a key determinant of therapy resistance (Figure 3).  
Of note, core cellular processes such as genomic integrity pathways and cell cycle 
progression are tightly associated to mitochondrial function. On the one hand, mitochondrial 
dysfunction is accompanied by depletion of nucleotide pools and this has been linked with the 
induction of DNA damage [59]. Beyond the well-established role of DNA damage in elicting 
genome instability and support tumorigenesis, high mutational burden has been linked to 
increased sensitivity to the checkpoint inhibitors anti-CTLA-4 [60] and anti-PD1 [61]. On the 
other hand, cell cycle checkpoint regulators Cyclin D3-CDK6 negatively regulate mitochondrial 
metabolism by drifting glucose-derived carbons away from the TCA and into the pentose-
phosphate pathway, hence supporting the production of antioxidant power [62]. This profound 
interplay between mitochondrial metabolism and core cellular checkpoints reveals the 
potential of targeting the activity of this organelle in  combination therapies to harness the 
vulnerabilities of tumor cells.  
Mitochondrial metabolism is heterogeneous within and between tumors [63], as evidenced 
in studies on cancer stem cell biology and antiangiogenic therapies [64-67]. These results 
suggest that the efficacy of anticancer therapy may depend on the intrinsic metabolic features 
of cancer cells. It also supports the notion that cancer cells endowed with higher adaptive 
metabolic capacity, or benefiting from the metabolic support of the microenvironment [68] can 
more easily escape drug toxicity. Furthermore, due to the association of cancer-initiating and 
therapy-resistant cells to a more oxidative metabolic program, it is tempting to speculate that: 
i) the emergence of therapy-resistant cancer clones relies on the newly acquired metabolic 
state, and ii) this metabolic plasticity can be therapeutically exploited through the combination 
of standard and anti-metabolic therapies (Figure 3).  
 Concluding Remarks 
Metabolic rewiring is a hallmark of cancer. Well-characterized changes in mitochondrial 
metabolism generally provide a growth advantage in an environment that supports cell 
proliferation. However, this program needs to be complemented by additional metabolic 
strategies to support anchorage-independent growth, metastatic dissemination, or 
pharmacological challenges. In this scenario, mutations in oncogenes and tumor suppressors 
can be seen as ways to reach new metabolic landscapes. Given that this metabolic 
reprogramming is tissue-specific, cancer cells might need to activate different gene networks 
depending on their tissue of origin. This hypothesis could explain why most of the well-
characterized oncogenes and tumor suppressors exhibit potent regulatory functions on the 
metabolic network, and why they are selected in specific tissues. The benefit of specific 
mitochondrial metabolic features at different stages of tumor progression and in response to 
therapy are yet to be clarified. Interestingly, changes in metabolism are frequently associated 
to epigenetic alterations through transcriptional or post-translational modifications, rather than 
irreversible genomic events. It is therefore possible that a specific metabolic landscape would 
enable epigenetic flexibility to control gene expression.  
Finally, although these metabolic adaptations might provide a selective advantage to 
cancer cells, they will likely unveil novel therapeutic vulnerabilities. Restricting the metabolic 
modulation of cancer cells and cornering them into a specific metabolic state, either by 
pharmacological strategies or changing nutrient availability, could be a strategy to hamper 
tumor progression and increase therapeutic efficacy. Understanding the different metabolic 
states that cancer cells can acquire upon therapeutic treatment is therefore crucial for the 
development of successful anticancer strategies.  
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 Figure legends 
 
Figure 1. Metabolic adaptations during cancer progression. Schematic representation of 
the evolution and progression of cancer, based on specific metabolic rewiring. Upon the 
establishment of an initial tumor mass, the acquisition of additional genetic mutations can lead 
to metabolic changes that will confer cancer cells different proliferative/survival capabilities. 
Survival of cancer cells and subsequent tumor progression is dependent on the acquisition of 
a successful metabolic state, defined here as metabolic flexibility. Please note that genetic 
mutations have been depicted as single consecutive events for simplicity, but various 
cumulative mutations can occur at each stage. 
 
Figure 2. Metabolic modulation during metastatic dissemination.  
Schematic representation of the stages of metastatic dissemination (proliferation, 
dissemination and metastasis). Right panel provides a summary of the metabolic adaptation 
exhibited by different tumor types and the estimated exposure to reactive oxygen species 
(ROS). *, glycolytic activity is presumed from results indicating reduced mitochondrial mass 
**, glycolytic activity is presumed from the progressive decrease in mitochondrial oxidative 
transcriptional programs from primary to metastatic cells. References: 1- Piskounova E. et al., 
Nature 2015; 2- Torrano V. et al., Nature Cell Biology 2016; 3- Le Bleu V.S. et al., Nature Cell 
Biology 2014; 4- Dupuy F. et al., Cell Metabolism 2015). Met: Metastasis. 
 
Figure 3. Metabolic modulation as a phenomenon underpinning therapy resistance. 
Schematic representation of how metabolic adaptations can enable resistance to anticancer 
therapies. The acquisition of drug resistance induces new metabolic essentialities that can be 
harnessed to specifically target resistant cells.  
  
 GLOSSARY 
Metastasis The process whereby, during tumor progression, cancer cells can leave the 
primary tumor mass and disseminate to other tissues and organs. Metastasis to vital organs 
is considered the main cause of death for cancer patients.  
 
Mitochondria Intracellular organelles at the core of cell metabolism involved in the coupling 
of oxygen consumption and nutrient catabolism to produce energy and metabolic 
intermediates for the cell. These are the sites where OXPHOS and TCA cycle occur. 
 
Metabolism It is the set of life-sustaining chemical reactions/transformations that occur 
within the cells of living organisms. 
 
Metabolic adaptation The intrinsic ability of the network of metabolic reactions to 
adapt to external stimuli (e.g. nutrient availability, pharmacological treatment) or internal 
alterations (e.g. mutations) in order to maintain cell homeostasis. Metabolic adaptation can 
allow to quickly change cellular phenotype and function. 
 
EMT  Epithelial-to-Mesenchymal Transition; a process in which epithelial cells loss 
adhesion properties and become mesenchymal cells with invasive and migratory capacities. 
 
FH  Fumarate Hydratase; mitochondrial enzyme that catalyzes the reversible 
hydration/dehydration of fumarate to malate in the TCA cycle. 
  
MtDNA Mitochondrial DNA 
 
OXPHOS Oxidative Phosphorylation; metabolic pathway that occurs in the mitochondria 
in which nutrients are oxidized releasing energy that is then converted into ATP.  
  
PC  Pyruvate Carboxylase; an enzyme that catalyzes the irreversible carboxylation 
of pyruvate to oxaloacetate (OAA). 
 
PDAC  Pancreatic Ductal Adenocarcinoma. 
 
PGC1 α Peroxisome proliferator-activated receptor γ co-activator 1 α; a transcriptional 
co-factor implicated in energy metabolism and the principal regulator of mitochondrial 
biogenesis. 
  
SDHA  Succinate Dehydrogenase A; Subunit of the succinate-ubiquinone 
oxidoreductase as part of the mitochondrial respiratory chain. Contains the FAD binding site 
where succinate is deprotonated and converted to fumarate. 
 
SRC  Proto-Oncogene Tyrosine-Protein Kinase. 
 
TCA  Tricarboxylic acid; Series of biochemical reactions used by all aerobic 
organisms to release energy (ATP) through oxidation of nutrients. 
 
TCGA  The Cancer Genome Atlas. 
 
